MedTrace Logo

Prospective Stratification of Infectious Risks in Multiple Sclerosis

NCT04036097 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 298

Last updated 2025-04-17

No results posted yet for this study

Summary

This monocentric study is to identify factors that increase the susceptibility for infections and establish a questionnaire-based infection score that allows a prospective stratification for infectious risks in patients with multiple sclerosis (MS) (InRIMS-Study). The study will utilize a validated, MS-adapted questionnaire and infection diary from the Airway Infection Susceptibility (AWIS) study in a regularly followed, prospective cohort of MS patients. It is a nested project of the prospective observational Swiss MS Cohort (SMSC) and SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation) studies.

Conditions

Interventions

OTHER

MS-adapted AWIS questionnaire (MS-AWIS)

The predefined questionnaire-based infection score of the Airway Infection Susceptibility (AWIS) study is predictive for the occurrence of respiratory tract infections (RTI). In addition several MS-specific items (e.g. bladder dysfunction and urinary tract infections) are included into the AWIS questionnaire (MS-AWIS).

OTHER

infection diary (MS-AWIS diary)

MS patients prospectively fill out monthly infection diaries for 24 months. Infection diaries will either be sent back (with pre-franked envelopes) or handed back to the InRIMS-study team during regular clinical visits (usually every 6 or 12 months).

Sponsors & Collaborators

  • Swiss Multiple Sclerosis Society

    collaborator UNKNOWN

  • Bangerter-Rhyner Stiftung

    collaborator UNKNOWN

  • Center for Chronic Immunodeficiency (CCI) in Freiburg, Germany

    collaborator UNKNOWN

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Bernhard Décard, Dr. med · University Hospital Basel, Department of Neurology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-10
Primary Completion
2022-12-31
Completion
2023-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04036097 on ClinicalTrials.gov